NxStage maintained at market outperform

JMP Securities analyst Robert C. Faulkner kept NxStage Medical, Inc. at market outperform. According to the analyst, users love the NxStage Dialysis system. With just 10% of the U.S. market, NxStage would realize more than $600 million. Shares of the Lawrence, Mass.-based medical products company were up 58 cents, or 7.61%, at $8.20 on volume of 148,207 shares versus the three-month running average of 131,769 shares. (Nasdaq: NXTM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.